The American stock market opens in mixed moods. Uncertainty in the market persists, and that doesn’t sit well with the markets. Reports from more U.S. companies point to an uncertain future, and forecasts include strongly conservative outlooks.
At the time of publication, futures on major U.S. indices slightly reduce gains from earlier in the day. Investors started the day in better spirits after positive news about negotiations between the U.S. and Japan. However, later statements from bankers slightly cooled investors’ emotions. As a result, at the opening of the cash session, we observe a slight reduction in gains. US500 gains +0.60%, US100 is quoted +0.40% higher, and US2000 +0.60%.
US100
Technology companies have not had the best time. A combination of economic uncertainty and high company valuations has caused a strong correction in many significant assets. US100 is currently consolidating around the 18,450-point level, which appears to be a relatively important consolidation zone. From the top, the index is capped by resistance above 19,000 points, and from the bottom supported above 17,250 points.
Source: xStation 5
Company news
Hertz Global (HTZ.US) gains 57% after Pershing Square disclosed a 4.1% stake, second only to Knighthead’s 58.9%. The investment sparked speculation of activist involvement and operational shifts, while analysts noted the rally could help Hertz raise $500M+ and support future AI-driven autonomous vehicle infrastructure.
MongoDB (MDB.US) gains 0.20% after Redburn upgraded the company to Neutral from Sell, citing limited downside risk. The analyst pointed out that MongoDB’s valuation is near record lows, with reset expectations, and issued a $170 price target, implying 6.2% upside.
Taiwan Semiconductor (TSM.US) gains 2.50% after Q1 profit surged 60% Y/Y on strong AI chip demand. The company guided Q2 revenue to $28.4B–$29.2B (vs. $27.22B expected) and sees 2025 revenue growing in the mid-20% range. Management also forecasts a 2024–2029 revenue CAGR near 20%, long-term gross margin of 53%+, and ROE above 25%.
Eli Lilly (LLY.US) is up by 15% after Phase 3 trial results for its oral GLP-1 drug showed ~8% (16 lbs) weight loss over 40 weeks in type 2 diabetes patients. The strong data strengthened Lilly’s position in the obesity drug market ahead of 2025–26 regulatory filings, putting pressure on rivals like Novo Nordisk (-8%).
Global Payments (GPN.US) declines 15.70% after announcing a $24.25B acquisition of the remaining stakes in Worldpay and divesting its Issuer Solutions business for $13.5B. Investors reacted negatively to the deal’s complexity, integration risks, and higher leverage. Meanwhile, FIS shares rose 6%, benefiting from improved margins and projected $275M+ in long-term synergies.
UnitedHealth (UNH.US) plummeted 20% after the insurer cut full-year adjusted EPS guidance to $26.00–$26.50 (vs. prior $29.50–$30.00 and $29.74 consensus). The miss on Q1 results dragged down sector peers, including Cigna (-3%), CVS (-6%), and Humana (-6%).
Alcoa (AA.US) dips 5% following mixed Q1 results and rising tariff concerns. Alcoa expects $90M in Q2 costs from U.S. aluminium tariffs (up from $20M in Q1), with annual profit impact estimated at $100M. CEO Oplinger also warned that tariffs on Chinese inputs could add $10M–$15M more annually.
The material on this page does not constitute financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other specific needs. All information provided, including opinions, market research, mathematical results and technical analyzes published on the Website or transmitted To you by other means, it is provided for information purposes only and should in no way be construed as an offer or solicitation for a transaction in any financial instrument, nor should the information provided be construed as advice of a legal or financial nature on which any investment decisions you make should be based exclusively To your level of understanding, investment objectives, financial situation, or other specific needs, any decision to act on the information published on the Website or sent to you by other means is entirely at your own risk if you In doubt or unsure about your understanding of a particular product, instrument, service or transaction, you should seek professional or legal advice before trading. Investing in CFDs carries a high level of risk, as they are leveraged products and have small movements Often the market can result in much larger movements in the value of your investment, and this can work against you or in your favor. Please ensure you fully understand the risks involved, taking into account investments objectives and level of experience, before trading and, if necessary, seek independent advice.
